Quintrio
Home

PHARMACEUTICAL PREPARATIONS

BeOne Medicines Ltd. American Depositary Shares

ONC

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Last trade $411.39
Day change +$0.10 (+0.02%)
Day range $403.31 – $412.61
Volume 124,961
Market cap $46.98B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$46.98B
Price / earnings
51.31×
Price / book
8.07×
Price / sales
7.11×
EV / sales
6.4×
EV / EBITDA
31.15×

Profitability

Earnings per share
$8.02
Return on assets
9.27%
Return on equity
15.73%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.18×
Current ratio
3.55×
Quick ratio
3.19×
Cash ratio
2.59×

Cash flow

Price / cash flow
29.54×
Price / free cash flow
32.42×
Free cash flow
$1.45B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ONC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$1.89B$1.71B$1.51B$1.5B$1.41B$1.32B$1.12B
Cost of revenue$216.9M$174.53M$167.22M$142.42M$196.51M$164.61M$165M
Gross profit$1.67B$1.53B$1.35B$1.36B$1.22B$1.15B$952.28M
Selling, general and administrative$593.46M$593.21M$555.1M$555.29M$529M$537.91M$459.29M
Research and development$660.78M$612.28M$541.22M$615.42M$523.66M$524.9M$481.89M
Total operating expenses$1.25B$1.21B$1.1B$1.17B$1.05B$1.06B$941.18M
Operating income$418.68M$325.05M$249.9M$185.04M$163.11M$87.89M$11.1M
Interest expense-$42.41M-$39.74M-$32.89M-$58.23M-$16.36M-$8M-$7M
Income before taxes$410.36M$312.46M$259.22M$149.24M$147.16M$99.55M$20.9M
Income taxes$25.65M$75.45M$31.86M$82.74M$22.32M$5.23M$19.63M
Net income$384.71M$237.01M$227.36M$66.5M$124.84M$94.32M$1.27M
Net income attributable to common shareholders$384.71M$237.01M$227.36M$66.5M$124.84M$94.32M$1.27M
EBITDA$479.61M$365.56M$291.05M$221.02M$200.4M$123.5M$43.91M
Basic earnings per share$0.26$0.16$0.16$0.05$0.09$0.07$0.00
Diluted earnings per share$0.25$0.16$0.15$0.04$0.08$0.06$0.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake

Revolution Medicines reported Q3 2026 results with a narrower-than-expected loss of $1.90 per share and revenues of $197.6 million, entirely from Rasonque sales following its FDA approval in late August. The drug reached over 5,000 patients in five weeks with strong reimbursement coverage. The company maintained its 2026 operating expense guidance and holds a strong cash position of $3.7 billion. European approval is pending, and multiple late-stage studies are underway for pancreatic cancer and other RAS-mutant cancers.

Zacks Investment Research

New Strong Buy Stocks for November 3rd

Five stocks have been added to the Zacks Rank #1 (Strong Buy) list, including Hewlett Packard Enterprise, AerCap Holdings, Ultrapar Participações, BeOne Medicines, and Bankwell Financial Group. These companies have shown consensus earnings estimate increases ranging from 7.4% to 15.2% over the last 60 days.

GlobeNewswire Inc.

BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight

The BTK inhibitors market is expected to experience steady growth through 2036, driven by increasing prevalence of B-cell malignancies, established clinical benefits, and an expanding pipeline of next-generation therapies. Key developments include FDA approvals for new indications and multiple drugs in clinical trials targeting oncology and autoimmune diseases across the 7MM markets.

Zacks Investment Research

All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy

BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy) rating, primarily driven by upward trends in earnings estimates. Over the past three months, the Zacks Consensus Estimate for the company has increased 53.4%. The upgrade positions the stock in the top 5% of Zacks-covered stocks, suggesting potential for near-term price appreciation based on improving earnings outlook.

Zacks Investment Research

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.